Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...